Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382:1894–905. https://doi.org/10.1056/NEJMoa1915745.

Article  CAS  PubMed  Google Scholar 

Kohya R, Suda G, Ohara M, Hosoda S, Sho T, Chuma M, et al. Serum FGF21 as a predictor of response to atezolizumab and bevacizumab in HCC. JHEP Rep. 2025;7: 101364. https://doi.org/10.1016/j.jhepr.2025.101364.

Article  PubMed  PubMed Central  Google Scholar 

Shen YC, Liu TH, Nicholas A, Soyama A, Yuan CT, Chen TC, et al. Clinical outcomes and histologic findings of patients with hepatocellular carcinoma with durable partial response or durable stable disease after receiving atezolizumab plus bevacizumab. J Clin Oncol. 2024;42:4060–70. https://doi.org/10.1200/JCO.24.00645.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chen VL, Xu D, Wicha MS, Lok AS, Parikh ND. Utility of liquid biopsy analysis in detection of hepatocellular carcinoma, determination of prognosis, and disease monitoring: a systematic review. Clin Gastroenterol Hepatol. 2020;18:2879–2902. https://doi.org/10.1016/j.cgh.2020.04.019

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cai Z, Chen G, Zeng Y, Dong X, Li Z, Huang Y, et al. Comprehensive liquid profiling of circulating tumor DNA and protein biomarkers in long-term follow-up patients with hepatocellular carcinoma. Clin Cancer Res. 2019;25:5284–94. https://doi.org/10.1158/1078-0432.CCR-18-3477.

Article  CAS  PubMed  Google Scholar 

Matsumae T, Kodama T, Myojin Y, Maesaka K, Sakamori R, Takuwa A, et al. Circulating cell-free DNA profiling predicts the therapeutic outcome in advanced hepatocellular carcinoma patients treated with combination immunotherapy. Cancers (Basel). 2022. https://doi.org/10.3390/cancers14143367.

Article  PubMed  PubMed Central  Google Scholar 

Baylin SB, Jones PA. Epigenetic determinants of cancer. Cold Spring Harb Perspect Biol. 2016. https://doi.org/10.1101/cshperspect.a019505

Article  PubMed  PubMed Central  Google Scholar 

Chen L, Flies DB. Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat Rev Immunol. 2013;13:227–242. https://doi.org/10.1038/nri3405

Article  CAS  PubMed  PubMed Central  Google Scholar 

Qureshi OS, Zheng Y, Nakamura K, Attridge K, Manzotti C, Schmidt EM, et al. Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4. Science. 2011;332:600–3. https://doi.org/10.1126/science.1202947.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tatsumi T, Takehara T, Katayama K, Mochizuki K, Yamamoto M, Kanto T, et al. Expression of costimulatory molecules B7–1 (CD80) and B7–2 (CD86) on human hepatocellular carcinoma. Hepatology. 1997;25:1108–14. https://doi.org/10.1002/hep.510250511.

Article  CAS  PubMed  Google Scholar 

Bruix J, Sherman M, Practice Guidelines Committee. Management of hepatocellular carcinoma. Hepatology. 2005. https://doi.org/10.1002/hep.20933

Article  PubMed  Google Scholar 

Vogel A, Chan SL, Dawson LA, Kelley RK, Llovet JM, Meyer T, et al. Hepatocellular carcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2025;36:491–506. https://doi.org/10.1016/j.annonc.2025.02.006.

Article  CAS  PubMed  Google Scholar 

Yang Z, Suda G, Maehara O, Ohara M, Yoda T, Sasaki T, et al. Changes in serum growth factors during resistance to atezolizumab plus bevacizumab treatment in patients with unresectable hepatocellular carcinoma. Cancers (Basel). 2023. https://doi.org/10.3390/cancers15030593.

Article  PubMed  PubMed Central  Google Scholar 

Sho T, Suda G, Ogawa K, Kimura M, Kubo A, Tokuchi Y, et al. Early response and safety of atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma in patients who do not meet IMbrave150 eligibility criteria. Hepatol Res. 2021;51:979–89. https://doi.org/10.1111/hepr.13693.

Article  CAS  PubMed  Google Scholar 

Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010;30:52–60. https://doi.org/10.1055/s-0030-1247132.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tanaka K, Tsuji K, Hiraoka A, Tada T, Hirooka M, Kariyama K, et al. Usefulness of tumor marker score for predicting the prognosis of hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: a multicenter retrospective study. Cancers (Basel). 2023. https://doi.org/10.3390/cancers15174348.

Article  PubMed  PubMed Central  Google Scholar 

Zhang Q, et al. CD86 is associated with immune infiltration and immunotherapy signatures in AML and promotes its progression. J Oncol. 2023;2023:9988405. https://doi.org/10.1155/2023/9988405

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tomasi TB, Magner WJ, Khan ANH. Epigenetic regulation of immune escape genes in cancer. Cancer Immunol Immunother. 2006;55:1159–84. https://doi.org/10.1007/s00262-006-0164-4.

Article  PubMed  PubMed Central  Google Scholar 

Watanabe T, et al. Circulating cell-free DNA as a biomarker for prognosis and response to systemic therapy in patients with unresectable hepatocellular carcinoma. Oncology. 2023;101:714–722. https://doi.org/10.1159/000531671

Article  CAS  PubMed  Google Scholar 

Tran NH, Kisiel J, Roberts LR. Using cell-free DNA for HCC surveillance and prognosis. JHEP Rep. 2021;3: 100304. https://doi.org/10.1016/j.jhepr.2021.100304

Article  PubMed  PubMed Central  Google Scholar 

Zhu AX, et al. Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma. Nat Med. 2022;28:1599–1611. https://doi.org/10.1038/s41591-022-01868-2

Article  CAS  PubMed  Google Scholar